ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Obituary: Eugene Schonfeld, Founder of Kidney Cancer Foundation

October 3, 1997

NKTR-102 Shows 29 Percent Response in Phase II Study

September 30, 2011

Five Group Chairs Discuss Mergers In A Q&A

March 11, 2011

NCI Clarifies Policy On Small, Short-Term Research Grants

July 5, 1996

Dana-Farber, Harvard And Affiliates Form Cancer Center.

February 4, 2000

Reviewers Note Major Flaws In Design Of Burzynski’s Trials

September 25, 1998